PR

Probi ABSTO Probi Stock Report

Last reporting period 30 Jun, 2024

Updated 11 Nov, 2024

Last price

Market cap $B

0.292

Micro

Exchange

XSTO - Nasdaq STOCKHOLM AB

PROB.ST Stock Analysis

PR

Avoid

Based on Eyestock quantitative analysis, PROB.ST`s fundamental data and valuation indicate an investment grade of Avoid at the current time.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

58/100

Moderate score

Upside

To determine whether the current price is a reasonable to buy a stock, we compare it to our estimate of fair value. The more undervalued a stock is, the higher the upside.

-76.2 %

Greatly overvalued

Market cap $B

0.292

Dividend yield

0.64 %

Shares outstanding

11.394 B

Probi AB engages in the development and sale of probiotics. The company is headquartered in Lund, Skane. The Company’s activities are divided into two business areas: Functional Foods, which focuses on the probiotics application in food in partnership with food companies; and Consumer Healthcares, which develops, commercializes and sells Probi probiotics in collaboration with a range of entities, such as pharmaceutical companies and firms related to the production of probiotics and self-care goods. Its brands portfolio comprises two trademarks: Probi Digestis and Probi Defendum. The firm's partners include Danone, Skanemejerier, NextFoods, Sanum Polska, Heinz, Kraft Foods, and Institut Rosell, among others. The firm is a parent of Probi Food AB and Probi Feed AB.

View Section: Eyestock Rating